The stock's fall snapped a six-day winning streak.

Boston Scientific BSX has delivered an impressive return over the past year, with shares rallying 40.5%. The performance outpaced the industry’s 14.3% gain and the S&P 500 composite’s 12.5% rise.

Boston Scientific (NYSE:BSX) recently entered into a significant agreement with Bittium Biosignals Ltd. to supply ECG devices, valued between USD 30 to 45 million, which strengthens their cardiac ...

Boston Scientific is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for BSX's full-year earnings has moved 2.3% higher.

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is ...

Boston Scientific BSX underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...

Boston Scientific’s Operating Cash Flow (OCF) for the same period was $3.8 billion, indicating a good OCF margin of 21.7% compared to the S&P 500’s 14.9%.

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Boston Scientific agreed to pay Johnson & Johnson $600 million in connection with Johnson & Johnson’s botched acquisition of Guidant, a medical device company, in 2004.

Boston Scientific has surged 40.5% in the past year, outpacing both its industry and the S&P 500. The WATCHMAN FLX and ...

Shares of Boston Scientific Corp. BSX slid 1.04% to $104.17 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.41% to 5,935. ...